Yahoo Search Búsqueda en la Web

The most sig­nif­i­cant ad­verse ef­fects of irinote­can are se­vere di­ar­rhea and ex­treme sup­pres­sion of the im­mune system.

Camp­tothecin, one of the four major struc­tural clas­si­fi­ca­tions of plant-de­rived anti-can­cer­ous com­pounds, is a cy­to­toxic al­ka­loid which con­sists of a pen­ta­cyclic ring struc­ture con­tain­ing a pyr­role (3, 4 β) quino­line moi­ety, an S-con­fig­ured lac­tone form, and a car­boxy­late form.Irinote­can is ac­ti­vated by hy­drol­y­sis ...

Irinote­can is con­verted by an en­zyme into its ac­tive metabo­lite SN-38, which is in turn in­ac­ti­vated by the en­zyme UGT1A1 by glu­curonida­tion.

Approval

Irinote­can re­ceived ac­cel­er­ated ap­proval from the U.S. Food and Drug Ad­min­is­tra­tion(FDA) in 1996 and full ap­proval in 1998.

Names

Dur­ing de­vel­op­ment, it was known as CPT-11.

A li­po­some en­cap­su­lated ver­sion of irinote­can sold as Onivyde, was ap­proved by FDA in Oc­to­ber 2015 to treat metasta­tic pan­cre­atic can­cer.It gained EU ap­proval in Oc­to­ber 2016.